In May 2026, Asian markets are witnessing a robust performance, with the technology sector taking center stage amid a backdrop of resilient domestic demand and optimism around AI-related advancements. As key indices like China's CSI 300 Index and Hong Kong's Hang Seng Index show positive momentum, investors are increasingly focusing on high-growth tech stocks that demonstrate strong fundamentals and adaptability to evolving market conditions.
Top 10 High Growth Tech Companies In Asia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Shengyi Electronics | 26.78% | 32.30% | ★★★★★★ |
| Eoptolink Technology | 38.55% | 40.46% | ★★★★★★ |
| Digital Arts | 22.02% | 27.25% | ★★★★★★ |
| Fositek | 28.54% | 37.56% | ★★★★★★ |
| Zhongji Innolight | 42.23% | 45.41% | ★★★★★★ |
| ISU Petasys | 27.23% | 34.54% | ★★★★★★ |
| Suzhou TFC Optical Communication | 42.81% | 41.23% | ★★★★★★ |
| Accton Technology | 28.69% | 33.12% | ★★★★★★ |
| Unimicron Technology | 29.75% | 54.18% | ★★★★★★ |
| CARsgen Therapeutics Holdings | 63.86% | 82.10% | ★★★★★★ |
Here we highlight a subset of our preferred stocks from the screener.
Aimed Bio (KOSDAQ:A0009K0)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Aimed Bio Inc. focuses on developing therapeutic solutions for brain diseases such as neuro-oncological and degenerative conditions, with a market cap of ₩2.65 trillion.
Operations: Aimed Bio Inc. specializes in creating treatments for brain-related diseases, targeting neuro-oncological and degenerative conditions.
Aimed Bio, a rising star in the biotech sector, has demonstrated robust growth metrics that outpace its industry peers. With an annual revenue increase projected at 30.1% and earnings expected to surge by 70.1% per year, the company's financial trajectory starkly contrasts with the broader Korean market's averages of 14.4% and 31.1%, respectively. Recent engagements, including presentations at prominent corporate days and an upcoming Annual General Meeting in Seoul, underscore its active role within the industry ecosystem. This proactive approach not only enhances visibility but also potentially secures strategic partnerships pivotal for sustained growth in a competitive landscape.
- Dive into the specifics of Aimed Bio here with our thorough health report.
Understand Aimed Bio's track record by examining our Past report.
Wuhan Dameng Database (SHSE:688692)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Wuhan Dameng Database Company Limited specializes in database product development services in China, with a market capitalization of CN¥29.97 billion.
Operations: The company generates revenue primarily from data processing services, amounting to CN¥1.46 billion.
Wuhan Dameng Database has carved a niche in the competitive tech landscape of Asia with its impressive financial performance, demonstrating a 23.7% increase in annualized revenue growth and an even more striking 24.8% rise in earnings growth per year. This outpaces the broader Chinese market's average, reflecting a robust demand for its database solutions. The company's commitment to innovation is evident from its R&D spending trends, which have strategically bolstered its technological advancements and product offerings. Recent financial reports highlight a surge in quarterly revenue to CNY 410.66 million from CNY 258.13 million year-over-year, alongside net income growth to CNY 151.41 million, up from CNY 98.16 million, showcasing strong operational execution and market acceptance of their technologies.
- Delve into the full analysis health report here for a deeper understanding of Wuhan Dameng Database.
Evaluate Wuhan Dameng Database's historical performance by accessing our past performance report.
Capcom (TSE:9697)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Capcom Co., Ltd. is a global entertainment company that engages in the planning, development, manufacturing, sales, and distribution of home video games, online games, mobile games, and arcade games with a market cap of ¥1.28 trillion.
Operations: The primary revenue stream for Capcom comes from its Digital Content segment, generating ¥144.28 billion, followed by Arcade Operations at ¥25.66 billion and Amusement Equipment at ¥17.78 billion.
Capcom, a stalwart in the gaming industry, continues to leverage its robust R&D framework, allocating JPY 32 billion in the last fiscal year to enhance its gaming and digital content segments. This investment supports Capcom's strategic focus on high-quality, immersive experiences as evidenced by a 7.3% rise in annual revenue and an 11% increase in earnings. Recent strategic alliances, like the one with GIGABYTE for Resident Evil™ Requiem, not only boost Capcom's market presence but also underline its commitment to integrating cutting-edge technology into its offerings. These collaborations are pivotal as they not only expand market reach but also enrich user engagement through innovative tech integrations.
- Unlock comprehensive insights into our analysis of Capcom stock in this health report.
Review our historical performance report to gain insights into Capcom's's past performance.
Summing It All Up
- Unlock more gems! Our Asian High Growth Tech and AI Stocks screener has unearthed 127 more companies for you to explore.Click here to unveil our expertly curated list of 130 Asian High Growth Tech and AI Stocks.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Wuhan Dameng Database might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:688692
Wuhan Dameng Database
Provides database product development services in China.
Flawless balance sheet with reasonable growth potential.
Market Insights
Weekly Picks

This small cap is building the AI workforce of the future

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Kraft Heinz (KHC): Less Drama, More Ketchup

Beyond 2026, Beyond a Double
Recently Updated Narratives

Very Bullish

Incluso con un colapso brutal del crédito KKR mantendría beneficios relevantes

Microsoft no es una apuesta. Es una franquicia global de la que se puede ser socio durante décadas.
Popular Narratives
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

The $135 Billion Bet That Should Make Every Shareholder Nervous
